Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates

Core Insights - Assertio (ASRT) reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -133.33% [1] - The company's revenues for the quarter ended March 2025 were $26.49 million, missing the Zacks Consensus Estimate by 5.23% and down from $32.45 million a year ago [2] - Assertio shares have declined approximately 30% year-to-date, contrasting with the S&P 500's decline of -3.8% [3] Financial Performance - Over the last four quarters, Assertio has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $27.54 million, and for the current fiscal year, it is -$0.12 on revenues of $116.78 million [7] Market Outlook - The estimate revisions trend for Assertio is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The Medical - Drugs industry, to which Assertio belongs, is ranked in the top 27% of over 250 Zacks industries, suggesting a favorable industry outlook [8]